ASX Share rice
Tue 04 Aug 2020 - 07:00:am (Sydney)

AVE Share Price

AVECHO BIOTECHNOLOGY LIMITEDAVEPharmaceuticals, Biotechnology & Life Sciences

AVE Company Information

Name:

Avecho Biotechnology Limited

Sector:

Healthcare

Industry:

Biotechnology

Address:

2A Westall Road Melbourne VIC Australia 3168

Phone:

61 3 9002 5000

COO & GM of Animal Health & Nutrition:

Dr. Roksan Libinaki

CEO & Chief Scientific Officer:

Dr. Paul Gavin

Company Sec. & CFO:

Ms. Melanie Leydin

Company Overview:

Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. The company operates through Production, Human Health, and Animal Health and Nutrition segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company serves customers in Australia, Switzerland, the United States, India, Japan, China, Singapore, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited is based in Melbourne, Australia.

AVE Share Price Information

Shares Issued:

1.58B

Market Capitalisation:

$12.62M

Revenue (TTM):

$4.24M

Revenue Per Share (TTM):

$0

Earnings per Share:

$0.001

Profit Margin:

0.2006

Operating Margin (TTM):

$0.12

Return On Assets (TTM):

$0.06

Return On Equity (TTM):

$0.20

Quarterly Revenue Growth (YOY):

-0.892

Gross Profit(TTM):

$4.02M

Diluted Earnings Per Share (TTM):

$0.001

AVE CashFlow Statement

CashFlow Date:

2019-12-31

Investments:

$11.06K

Change To Liabilities:

$-390,375

Total Cashflow From Investing Activities:

$11.06K

Net Borrowings:

$-89,439

Net Income:

$849.96K

Total Cash From Operating Activities:

$1.18M

Depreciation:

$683.46K

Other Cashflow From Investing Activities:

$11.06K

Change To Inventory:

$-48,914

Change To Account Receivables:

$-78,403

Capital Expenditures:

$0

AVE Income Statement

Income Date:

2019-12-31

Income Before Tax:

$849.96K

Net Income:

$849.96K

Gross Profit:

$4.02M

Operating Income:

$502.30K

Other Operating Expenses:

$762.64K

Interest Expense:

$11.03K

Total Revenue:

$4.24M

Total Operating Expenses:

$3.52M

Cost Of Revenue:

$214.57K

AVE Balance Sheet

Balance Sheet Date:

2019-12-31

Intangible Assets:

$857K

Total Liabilities:

$556.13K

Total Stockholder Equity:

$4.76M

Other Current Liabilities:

$32.79K

Total Assets:

$5.32M

Common Stock:

$232.63M

Other Current Assets:

$163.41K

Retained Earnings:

$-256,026,293

Other Liabilities:

$3.60K

Cash:

$3.21M

Total Current Liabilities:

$544.83K

Property - Plant & Equipment:

$179.93K

Net Tangible Assets:

$3.90M

Total Current Assets:

$4.28M

Net Receivables:

$151.99K

Short-Term Investments:

$1.04M

Inventory:

$148.76K

Accounts Payable:

$96.58K

Non Currrent Assets (Other):

$1.04M

Short-Term Investments:

$1.04

Non Current Liabilities Total:

$11.30K

AVE Share Price History

AVE News

17 Apr, 2020
Avecho Biotechnology's's (ASX:AVE) stock is up by a considerable 200% over the past month. Given the company's...
14 Jan, 2020
Ross Murdoch has been the CEO of Avecho Biotechnology Limited (ASX:AVE) since 2015. This analysis aims first to...
12 Nov, 2019
Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we...